CDH1 Gene rs1801552 C/T Polymorphism Increases Susceptibility to Esophageal Squamous Cell Carcinoma but Not to Gastric Cardiac Adenocarcinoma

Abstract

Purpose

The present study aimed to investigate whether the single nucleotide polymorphism (SNP) rs1801552 C/T in CDH1 gene is correlated with the risk of esophageal squamous cell carcinoma (ESCC) and gastric cardiac adenocarcinoma (GCA), as a preliminary study.

Methods

The rs1801552 C/T polymorphism was genotyped by the method of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 1316 cancer patients (810 ESCC and 506 GCA) and 1966 controls in north China. We performed two case–control studies, each of which included a population-based set and a hospital-based set.

Results

The data showed that the rs1801552 C/T polymorphism was associated with the risk of ESCC. Allelotype and genotype distributions of the rs1801552 C/T polymorphism in ESCC patients of high-incidence region and hospital were significantly different from that in their respective controls (p < 0.05). Compared with C/C genotype, T/T genotype increased the risk of ESCC in high-incidence region and hospital (age, sex, smoking status and family history of UGIC adjusted odds ratio (OR) = 1.79 and 2.10, 95% confidence interval (CI) = 1.23–2.60 and 1.10–4.04, respectively). Allelotype and genotype distributions of the rs1801552 C/T polymorphism in GCA patients were not significantly different from that in their controls, respectively (p > 0.05).

Conclusions

The findings in the present pilot study suggest that the rs1801552 C/T polymorphism was associated with the risk of ESCC, but was not associated with the risk of GCA in high-incidence region and hospital.

Keywords:

• CDH1 gene
• polymorphism
• esophageal squamous cell carcinoma
• gastric cardiac adenocarcinoma

Acknowledgments

We declare that this research contained in the manuscript has not been published, and the manuscript is not under consideration elsewhere. All authors have participated in the concept and design, analysis and interpretation of data, drafting or revising of the manuscript, and that they have approved the manuscript as submitted. Authors must state their study does not violate the policies and/or procedures established by journal.

Disclosure statement

The authors reported no conflict of interest related to this article. None of the authors has a financial or corporate relationship.